



NDA 20-988/S-003

Wyeth-Ayerst Laboratories  
Attention: Caroline M. Henesey, Ph.D.  
Manager, Worldwide Regulatory Affairs  
P.O. Box 8299  
Philadelphia, PA 19101-8299

19 OCT 2001

Dear Dr. Henesey:

Please refer to your supplemental new drug application dated April 19, 2001, received April 20, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Protonix<sup>®</sup> I.V. (pantoprazole sodium) for Injection, equivalent to 40 mg.

We acknowledge receipt of your submissions dated July 11, September 24, and October 15, 2001, as well as your facsimile dated October 17, 2001.

This supplemental new drug application provides for the use of Protonix<sup>®</sup> I.V. for Injection in the treatment of pathological hypersecretion associated with Zollinger-Ellison Syndrome (ZES).

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-988/S-003." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that a waiver was issued on April 2, 2001 for pediatric studies of hypersecretory conditions, including Zollinger-Ellison Syndrome, since the incidence is low in the pediatric population.

Pediatric studies conducted under the terms of section 505A of the Federal Food, Drug, and Cosmetic Act may result in additional marketing exclusivity for certain products (pediatric exclusivity). You should refer to the *Guidance for Industry on Qualifying for Pediatric Exclusivity* (available on our web site at [www.fda.gov/cder/pediatric](http://www.fda.gov/cder/pediatric)) for details. We acknowledge your January 19, 2001 submission of an amended version of your January 31, 2000 proposed pediatric study request with pantoprazole sodium to support the issuance of a Written Request. Your proposal is being reviewed. FDA generally will not accept studies submitted to an NDA before issuance of a Written Request as responsive to a Written Request. Sponsors should obtain a Written Request before submitting pediatric studies to an NDA. Please note that satisfaction of the requirements in 21 CFR 314.55 alone may not qualify you for pediatric exclusivity. FDA does not necessarily ask a sponsor to complete the same scope of studies to qualify for pediatric exclusivity as it does to fulfill the requirements of the pediatric rule.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Cheryl Perry, Regulatory Health Project Manager, at (301) 827-7475.

Sincerely,

Victor F. C. Raczkowski, M.D., M.Sc.  
Acting Director  
Division of Gastrointestinal and Coagulation Drug Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research